Monoclonal antibodies (mAbs) target specific immune system components to treat autoimmune diseases like rheumatoid arthritis and multiple sclerosis. Drugs like adalimumab block TNF-alpha to reduce inflammation, while ocrelizumab targets B-cells in MS. Recent advances improve mAb specificity and reduce immunogenicity.
Challenges include high production costs and infusion-related reactions. Biosimilars are emerging to increase affordability. Research explores bispecific antibodies targeting multiple pathways simultaneously.
KAMARAJ R , et al. "Monoclonal Antibodies in Autoimmune Diseases".
OpenJournal system, VOL 1, Issue 1, Case Study.DOI: https://doi.org/4l8291970342986989